Results 81 to 90 of about 2,479 (207)

The first interim analysis of Italian patients enrolled in the real-world, Pan-European, prospective, observational, phase 4 PEARL study of fremanezumab effectiveness [PDF]

Introduction: In 2020, the Italian Medicines Agency (AIFA) approved the reimbursement of calcitonin gene-related peptide (CGRP) pathway monoclonal antibodies (mAbs), including fremanezumab, in patients with a Migraine Disability Assessment Scale (MIDAS ...
Anna, Ambrosini, Antonio, Granato, Barbanti, Piero, Cepparulo, Mario, Chiara, Benedetto, Ester, Reggio, Fabrizio, Vernieri., Filippo Brighina, Finocchi, Cinzia, Florindo, D'Onofrio, Francesco, Perini, Geppetti, Pierangelo, Gianluca, Coppola, Giuliano, Sette, Innocenzo, Rainero, Kokturk, Pinar, Marco, Bartolini, Maria Pia, Prudenzano, Mariarosaria, Valente, Monica, Bandettini, Paola, Di Fiore, Paola, Sarchielli, Renata, Rao, Roberto, De Simone, Rosario, Iannacchero, Russo, Antonio, Sabina, Cevoli, Sacco, Simona, Sara, Gori, Simona, Guerzoni, Stefano, Messina, Susanna, Usai, Tassorelli, Cristina   +32 more
core   +1 more source

MIDAS and HIT‐6 Questionnaires Versus Headache Diaries for Monitoring Treatment Response to Erenumab in Migraine: A REFORM Study

European Journal of Neurology, Volume 33, Issue 4, April 2026.
Treatment response to anti‐CGRP medications for migraine is typically defined as a ≥ 50% reduction in monthly migraine days. However, the use of patient‐reported outcome measures (such as MIDAS and HIT‐6) has been proposed as alternative options.
Janu Thuraiaiyah, Rune Häckert Christensen, Haidar M. Al‐Khazali, Messoud Ashina, Zaza Katsarava, Håkan Ashina   +5 more
wiley   +1 more source

Real-world efficacy and tolerability of fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, observational study

Frontiers in Neurology, 2023
BackgroundFollowing the promising pre-marketing placebo-controlled randomized clinical trials of fremanezumab, post-marketing studies are necessary to verify efficacy and tolerability in various real-world settings.
Christopher Kjaer Cullum, Christopher Kjaer Cullum, Basit Ali Chaudhry, Basit Ali Chaudhry, Thien Phu Do, Thien Phu Do, Thien Phu Do, Faisal Mohammad Amin, Faisal Mohammad Amin, Faisal Mohammad Amin   +9 more
doaj   +1 more source

Are quarterly fremanezumab injections as effective as monthly fremanezumab injections at reducing the number of migraine days per month in adults with chronic migraines? [PDF]

, 2022
OBJECTIVE: The objective of this systematic EBM review is to determine “Are quarterly fremanezumabinjections as effective as monthly fremanezumab injections at reducing the number of migraine days per month in adults with chronic migraines?” STUDY DESIGN:
Mellinger, Elaine
core   +1 more source

Fremanezumab for prophylaxis of migraine in adults [PDF]

Prescriber, 2020
Fremanezumab (Ajovy) is a new anti‐CGRP monoclonal antibody therapy indicated for the prophylaxis of migraine in adults. This article outlines its properties, efficacy, adverse effects and place in therapy.
openaire   +1 more source

The Relevance of Crystal Clear and Unclear Days to Evaluate Residual Interictal Burden in Patients With Migraine Treated With CGRP Monoclonal Antibodies

European Journal of Neurology, Volume 33, Issue 4, April 2026.
ABSTRACT Background Although treatment goals in migraine prevention have moved beyond the benchmark of a 50% reduction in monthly attacks, residual disease burden is still evaluated based on residual headache frequency. However, migraine‐related symptoms can persist despite headache freedom, leading to so‐called unclear days that may meaningfully ...
Marcello Silvestro, Ilaria Orologio, Raffaele Ornello, Francesca Trojsi, Alessandro Tessitore, Simona Sacco, Antonio Russo   +6 more
wiley   +1 more source

A retrospective analysis of migraine prophylaxis with anti-CGRP monoclonal antibodies at the hospital of Lithuanian University of Health Sciences Kaunas Clinics

Neurologijos seminarai, 2023
Background. Migraine is a primary headache disorder described by episodic attacks that can progress to chronic migraine. Preventive treatment of anti-calcitonin gene-related peptide monoclonal antibodies (anti-CGRP mAbs) is currently being widely ...
V. Karpavičiūtė, K. Statkevičienė, G. Žemgulytė   +2 more
doaj   +1 more source

Reasons for patient reluctance to take preventive medications for migraine: Results of the OVERCOME (US) study

Headache: The Journal of Head and Face Pain, Volume 66, Issue 4, Page 846-858, April 2026.
Abstract Objectives/Background This study was undertaken to evaluate patient reasons for nonadoption of migraine‐preventive medications. Despite clear recommendations and eligibility criteria for migraine‐preventive treatment by the American Headache Society and the availability of these treatments, many people with migraine are not taking appropriate ...
Jessica Ailani, Rose Okonkwo, Elizabeth Johnston, Helen Hochstetler, Betzaida Martinez, Anthony Zagar, Robert A. Nicholson, Bert B. Vargas, E. Jolanda Muenzel, Richard B. Lipton   +9 more
wiley   +1 more source

Persistent Trigeminal Neuralgia‐Like Pain Following Isolated Hyaluronic Acid Lip Augmentation: A Case Report

Journal of Cosmetic Dermatology, Volume 25, Issue 4, April 2026.
ABSTRACT Background Hyaluronic acid (HA) fillers are widely used for lip augmentation and are generally associated with a favorable safety profile. While vascular complications are well recognized, non‐vascular neurological adverse events, including trigeminal neuropathic pain, remain underreported, particularly following procedures in anatomically ...
Rocco Salvatore Calabrò, Piera Bonavita
wiley   +1 more source

FREMANEZUMAG (FREMANEZUMAB DAN MAGNESIUM) SEBAGAI INOVASI DALAM PENCEGAHAN SERANGAN MIGRAIN [PDF]

, 2020
Migrain adalah penyakit yang dirasakan seumur hidup, sering berulang dan menghambat aktivitas penderitanya. Patogenesis migrain dispekulasikan berada pada sistem trigeminal dengan aktivitas neurotransmitter seperti CGRP, glutamat, serotonin dan nitrit ...
Qalbissilmi, Safira, Rahman, Putri Windiana   +1 more
core   +1 more source